These findings suggest CFI may regulate GBM vasculature through potential mechanisms such as angiogenesis modulation or vascular microenvironment remodeling (though the precise mechanisms remain uncharacterized), positioning it as a candidate anti-angiogenic target. The gene discussed is CFI; the disease is glioblastoma.